About Flex Pharma (NASDAQ:FLKS)
Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps and spasms associated with neurological conditions and exercise-associated muscle cramps in the United States. The company operates through two segments, Consumer Operations and Drug Development. Its lead drug candidate includes FLX-787, a single molecule, chemically synthesized, and transient receptor potential ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis and amyotrophic lateral sclerosis. The company also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. It markets and sells its HOTSHOT product online through its e-commerce Website, as well as through third-party Websites. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FLKS
CUSIPN/A
Phone617-874-1821
Debt
Debt-to-Equity RatioN/A
Current Ratio5.91%
Quick Ratio5.84%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.27 million
Price / Sales77.40
Cash FlowN/A
Price / CashN/A
Book Value$1.62 per share
Price / Book3.38
Profitability
EPS (Most Recent Fiscal Year)($1.99)
Net Income$-34,430,000.00
Net Margins-2,698.59%
Return on Equity-85.02%
Return on Assets-75.97%
Miscellaneous
Employees22
Outstanding Shares17,970,000
Flex Pharma (NASDAQ:FLKS) Frequently Asked Questions
What is Flex Pharma's stock symbol?
Flex Pharma trades on the NASDAQ under the ticker symbol "FLKS."
How were Flex Pharma's earnings last quarter?
Flex Pharma Inc (NASDAQ:FLKS) announced its quarterly earnings results on Wednesday, March, 7th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.10. The biotechnology company had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.36 million. Flex Pharma had a negative net margin of 2,698.59% and a negative return on equity of 85.02%. View Flex Pharma's Earnings History.
When is Flex Pharma's next earnings date?
What price target have analysts set for FLKS?
4 brokers have issued twelve-month target prices for Flex Pharma's stock. Their predictions range from $6.00 to $12.00. On average, they expect Flex Pharma's share price to reach $9.50 in the next twelve months. View Analyst Ratings for Flex Pharma.
What are Wall Street analysts saying about Flex Pharma stock?
Here are some recent quotes from research analysts about Flex Pharma stock:
- 1. According to Zacks Investment Research, "Flex Pharma, Inc. is a biotechnology company. The Company is involved in developing treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Flex Pharma, Inc. is headquartered in Boston, Massachusetts. " (4/18/2018)
- 2. Cantor Fitzgerald analysts commented, "Exploratory Phase II study of FLX-787 in MS showed statistically significant reduction of 27.3% (p=0.001) in frequency of cramps and a 1.4-day increase in the number of cramp-free days (p=0.0457)." (3/27/2018)
Who are some of Flex Pharma's key competitors?
Some companies that are related to Flex Pharma include Zafgen (ZFGN), Spero Therapeutics (SPRO), Summit Therapeutics (SMMT), Nabriva Therapeutics (NBRV), Xoma (XOMA), Protagonist Therapeutics (PTGX), Kamada (KMDA), Immune Design (IMDZ), Proteostasis Therapeutics (PTI), Spring Bank Pharmaceuticals (SBPH), Avid Bioservices (CDMO), XBiotech (XBIT), Intec Pharma (NTEC), NewLink Genetics (NLNK), Newron Pharmaceuticals (NWPHF), Teligent (TLGT), Tetraphase Pharmaceuticals (TTPH) and Acer Therapeutics (ACER).
Who are Flex Pharma's key executives?
Flex Pharma's management team includes the folowing people:
- Dr. Christoph H. Westphal, Co-Founder & Chairman (Age 51)
- Dr. Roderick MacKinnon Ph.D., M.D., Co-Founder, Co-Chair of Scientific Advisory Board and Director (Age 62)
- Dr. Thomas C. Wessel M.D., Ph.D., Chief Medical Officer (Age 62)
- Dr. William K. McVicar, Pres & CEO (Age 60)
- Mr. Robert Hadfield, Advisor (Age 40)
When did Flex Pharma IPO?
(FLKS) raised $60 million in an IPO on Thursday, January 29th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers.
Has Flex Pharma been receiving favorable news coverage?
Press coverage about FLKS stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Flex Pharma earned a daily sentiment score of 0.09 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 47.00 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Flex Pharma?
Shares of FLKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Flex Pharma's stock price today?
One share of FLKS stock can currently be purchased for approximately $5.47.
How big of a company is Flex Pharma?
Flex Pharma has a market capitalization of $98.13 million and generates $1.27 million in revenue each year. The biotechnology company earns $-34,430,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Flex Pharma employs 22 workers across the globe.
How can I contact Flex Pharma?
Flex Pharma's mailing address is 800 Boylston Street 24thFloor, Boston MA, 02199. The biotechnology company can be reached via phone at 617-874-1821 or via email at [email protected]
MarketBeat Community Rating for Flex Pharma (FLKS)
MarketBeat's community ratings are surveys of what our community members think about Flex Pharma and other stocks. Vote "Outperform" if you believe FLKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLKS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Flex Pharma (NASDAQ:FLKS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Flex Pharma in the last 12 months. Their average twelve-month price target is $9.50, suggesting that the stock has a possible upside of 73.67%. The high price target for FLKS is $12.00 and the low price target for FLKS is $6.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.75 | 2.80 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $9.50 | $9.50 | $10.50 | $11.00 |
| Price Target Upside: | 73.67% upside | 102.13% upside | 169.23% upside | 219.77% upside |
Flex Pharma (NASDAQ:FLKS) Consensus Price Target History
Flex Pharma (NASDAQ:FLKS) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Flex Pharma (NASDAQ:FLKS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Flex Pharma (NASDAQ FLKS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 45.36%
Institutional Ownership Percentage: 28.96%
Flex Pharma (NASDAQ FLKS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/8/2016 | Christoph H Westphal | Insider | Buy | 7,000 | $7.31 | $51,170.00 | 3,941,118 |  |
| 11/7/2016 | Christoph H Westphal | Insider | Buy | 8,870 | $5.70 | $50,559.00 | 3,934,118 | |
| 11/7/2016 | John P Mccabe | VP | Buy | 1,650 | $6.01 | $9,916.50 | 1,650 | |
| 6/23/2016 | Christoph H Westphal | CEO | Buy | 2,700 | $11.28 | $30,456.00 | 3,925,248 | |
| 6/22/2016 | Christoph H Westphal | CEO | Buy | 5,700 | $11.05 | $62,985.00 | 3,925,248 | |
| 6/21/2016 | Christoph H Westphal | CEO | Buy | 2,800 | $11.07 | $30,996.00 | 3,925,248 | |
| 6/20/2016 | Christoph H Westphal | CEO | Buy | 6,000 | $11.18 | $67,080.00 | 3,925,248 | |
| 6/16/2016 | Christoph H Westphal | CEO | Buy | 5,800 | $11.17 | $64,786.00 | 3,925,248 | |
| 6/14/2016 | Christoph H Westphal | CEO | Buy | 5,900 | $11.54 | $68,086.00 | 3,925,248 | |
| 6/10/2016 | Christoph H Westphal | CEO | Buy | 6,000 | $11.94 | $71,640.00 | 3,925,248 | |
| 6/8/2016 | Christoph H Westphal | CEO | Buy | 5,900 | $12.25 | $72,275.00 | 3,925,248 | |
| 6/6/2016 | Christoph H Westphal | CEO | Buy | 6,000 | $12.56 | $75,360.00 | 3,925,248 | |
| 6/2/2016 | Christoph H Westphal | CEO | Buy | 10,000 | $12.99 | $129,900.00 | 3,925,248 | |
| 5/31/2016 | Christoph H Westphal | CEO | Buy | 22,300 | $12.68 | $282,764.00 | 3,925,248 | |
| 5/26/2016 | Christoph H Westphal | CEO | Buy | 28,600 | $12.84 | $367,224.00 | 3,925,248 | |
| 5/24/2016 | Christoph H Westphal | CEO | Buy | 30,334 | $12.42 | $376,748.28 | 3,925,248 | |
| 5/20/2016 | Christoph H Westphal | CEO | Buy | 7,914 | $11.06 | $87,528.84 | 3,925,248 | |
| 5/18/2016 | Christoph H Westphal | CEO | Buy | 33,400 | $11.10 | $370,740.00 | 3,925,248 | |
| 5/16/2016 | Christoph H Westphal | CEO | Buy | 15,469 | $10.25 | $158,557.25 | 3,925,248 | |
| 5/12/2016 | Christoph H Westphal | CEO | Buy | 30,217 | $10.12 | $305,796.04 | 3,925,248 | |
| 5/10/2016 | Christoph H Westphal | CEO | Buy | 30,109 | $9.94 | $299,283.46 | 3,925,248 | |
| 3/24/2016 | Christoph H Westphal | CEO | Buy | 49,563 | $11.06 | $548,166.78 | 3,925,248 | |
| 3/22/2016 | Christoph H Westphal | CEO | Buy | 23,951 | $11.78 | $282,142.78 | | |
| 3/21/2016 | Christoph H Westphal | CEO | Buy | 48,058 | $11.74 | $564,200.92 | 3,925,248 | |
| 3/18/2016 | Christoph H Westphal | CEO | Buy | 37,574 | $11.00 | $413,314.00 | 3,925,248 | |
| 3/16/2016 | Christoph H Westphal | CEO | Buy | 38,379 | $10.23 | $392,617.17 | 3,925,248 | |
| 3/15/2016 | Michelle Stacy | Director | Buy | 2,585 | $9.63 | $24,893.55 | 2,585 | |
| 3/14/2016 | Thomas Wessel | Insider | Buy | 20,000 | $7.94 | $158,800.00 | 49,064 | |
| 3/11/2016 | Christoph H Westphal | CEO | Buy | 89,680 | $7.00 | $627,760.00 | 3,925,248 | |
| 3/11/2016 | Roderick Mackinnon | Director | Buy | 10,000 | $7.03 | $70,300.00 | 431,277 | |
| 12/14/2015 | Christoph H Westphal | CEO | Buy | 927 | $12.01 | $11,133.27 | 3,925,248 | |
| 12/7/2015 | Christoph H Westphal | CEO | Buy | 907 | $12.02 | $10,902.14 | 3,924,321 | |
| 11/19/2015 | Marc D Kozin | Director | Buy | 4,500 | $11.38 | $51,210.00 | 4,500 | |
| 11/16/2015 | Christoph H Westphal | CEO | Buy | 1,001 | $10.78 | $10,790.78 | 3,921,556 | |
| 11/9/2015 | Christoph H Westphal | CEO | Buy | 1,000 | $11.03 | $11,030.00 | 3,920,555 | |
| 10/26/2015 | Christoph H Westphal | CEO | Buy | 1,043 | $10.55 | $11,003.65 | 3,918,588 | |
| 10/19/2015 | Christoph H Westphal | CEO | Buy | 1,018 | $10.61 | $10,800.98 | 3,917,545 | |
| 9/28/2015 | Christoph H Westphal | CEO | Buy | 924 | $11.18 | $10,330.32 | 3,914,735 | |
| 3/30/2015 | Christoph H Westphal | CEO | Buy | 272 | $20.52 | $5,581.44 | | |
(Data available from 1/1/2013 forward)
Flex Pharma (NASDAQ FLKS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Flex Pharma (FLKS) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 11:10 AM |
| $300,000.00 in Sales Expected for Flex Pharma Inc (FLKS) This Quarter
www.americanbankingnews.com - April 15 at 2:14 AM |
| Brokerages Anticipate Flex Pharma Inc (FLKS) Will Announce Earnings of -$0.50 Per Share
www.americanbankingnews.com - April 13 at 9:16 PM |
| Flex Pharma Inc (FLKS) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 10 at 1:41 AM |
| Flex Pharma (FLKS) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 8 at 12:40 AM |
| Flex Pharma (FLKS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 7 at 3:53 PM |
| Flex Pharma (FLKS) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 31 at 4:56 PM |
| Flex Pharma (FLKS) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 31 at 12:10 PM |
| Brokerages Expect Flex Pharma Inc (FLKS) Will Announce Quarterly Sales of $300,000.00
www.americanbankingnews.com - March 29 at 2:28 AM |
| Flex Pharma (FLKS) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - March 28 at 10:22 PM |
 | Flex Pharma (FLKS) Announces Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in Multiple Sclerosis
www.streetinsider.com - March 28 at 8:59 AM |
| Zacks: Analysts Expect Flex Pharma Inc (FLKS) to Post -$0.50 Earnings Per Share
www.americanbankingnews.com - March 27 at 11:14 PM |
| Flex Pharma (FLKS) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - March 27 at 9:53 AM |
 | Flex Pharma's FLX-787 shows treatment effect in MS patients with cramps/spasms in exploratory study; shares up 6%
seekingalpha.com - March 26 at 4:53 PM |
 | Today’s Research Reports on Stocks to Watch: Flex Pharma, Inc. and Alexion Pharmaceuticals
finance.yahoo.com - March 16 at 8:53 AM |
| Flex Pharma Inc (FLKS) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 16 at 1:36 AM |
| Flex Pharma (FLKS) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - March 16 at 12:48 AM |
| Research Analysts Offer Predictions for Flex Pharma Inc's Q1 2018 Earnings (FLKS)
www.americanbankingnews.com - March 12 at 2:30 AM |
| Flex Pharma (FLKS) Posts Earnings Results, Beats Expectations By $0.10 EPS
www.americanbankingnews.com - March 8 at 10:29 AM |
| Cantor Fitzgerald Analysts Give Flex Pharma (FLKS) a $6.00 Price Target
www.americanbankingnews.com - March 7 at 4:15 PM |
 | Flex Pharma Reports Year End 2017 Financial Results
www.bizjournals.com - March 7 at 8:51 AM |
| Should You Buy Flex Pharma Inc (NASDAQ:FLKS) Now?
finance.yahoo.com - March 7 at 8:51 AM |
| Flex Pharma to Report Fourth Quarter and Full Year 2017 Results on March 7, 2018
finance.yahoo.com - February 28 at 5:38 PM |
| Flex Pharma (FLKS) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - February 27 at 2:34 AM |
| $360,000.00 in Sales Expected for Flex Pharma Inc (FLKS) This Quarter
www.americanbankingnews.com - February 23 at 2:02 AM |
| Zacks: Analysts Expect Flex Pharma Inc (FLKS) to Post -$0.85 EPS
www.americanbankingnews.com - February 21 at 11:14 PM |
| Flex Pharma Inc (FLKS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 19 at 1:32 AM |
| Zacks Investment Research Upgrades Flex Pharma (FLKS) to Hold
www.americanbankingnews.com - February 15 at 11:22 PM |
| Flex Pharma Inc to Post FY2018 Earnings of ($1.68) Per Share, Jefferies Group Forecasts (FLKS)
www.americanbankingnews.com - February 15 at 11:40 AM |
| Jefferies Group Comments on Flex Pharma Inc's FY2022 Earnings (FLKS)
www.americanbankingnews.com - February 14 at 4:12 PM |
| New Study Shows HOTSHOT™ Provides Relief From Muscle Soreness For Athletes Of All Types
finance.yahoo.com - February 8 at 8:29 AM |
| Flex Pharma Presenting at BIO CEO on February 13, 2018
finance.yahoo.com - February 6 at 4:00 PM |
| Summit Therapeutics (SMMT) vs. Flex Pharma (FLKS) Head-To-Head Contrast
www.americanbankingnews.com - February 6 at 1:19 PM |
| Flex Pharma (FLKS) Receives New Coverage from Analysts at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - January 27 at 7:12 PM |
| Flex Pharma Inc (FLKS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 25 at 9:48 AM |
| Zacks: Brokerages Anticipate Flex Pharma Inc (FLKS) Will Announce Quarterly Sales of $370,000.00
www.americanbankingnews.com - January 20 at 2:48 AM |
| Flex Pharma Inc (FLKS) Expected to Announce Earnings of -$0.85 Per Share
www.americanbankingnews.com - January 18 at 11:28 PM |
| Cantor Fitzgerald Reaffirms Hold Rating for Flex Pharma (FLKS)
www.americanbankingnews.com - January 18 at 1:50 PM |
 | Primecap Buys More Flex Pharma, Alkermes Stock
www.msn.com - January 5 at 10:10 AM |
| Breaking Down Flex Pharma Inc’s (NASDAQ:FLKS) Ownership Structure
finance.yahoo.com - January 3 at 4:53 PM |
| Roth Capital Reiterates Buy Rating for Flex Pharma (FLKS)
www.americanbankingnews.com - January 3 at 10:58 AM |
| -$0.98 EPS Expected for Flex Pharma Inc (FLKS) This Quarter
www.americanbankingnews.com - January 2 at 5:26 AM |
| Flex Pharma (FLKS) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - December 27 at 11:38 PM |
| ETFs with exposure to Flex Pharma, Inc. : December 26, 2017
finance.yahoo.com - December 27 at 3:33 PM |
| What Is Flex Pharma Inc’s (NASDAQ:FLKS) Financial Position?
finance.yahoo.com - December 27 at 3:33 PM |
| Flex Pharma, Inc. :FLKS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017
finance.yahoo.com - December 22 at 10:10 AM |
| Head-To-Head Review: Flex Pharma (FLKS) & Its Rivals
www.americanbankingnews.com - December 21 at 7:48 AM |
| Analysts Expect Flex Pharma, Inc. (FLKS) Will Post Quarterly Sales of $400,000.00
www.americanbankingnews.com - December 18 at 10:52 AM |
| Flex Pharma (FLKS) vs. The Competition Head-To-Head Contrast
www.americanbankingnews.com - December 9 at 1:22 AM |
| Should You Be Content With Flex Pharma Inc’s (FLKS) 18.4% Earnings Growth?
finance.yahoo.com - December 6 at 10:19 AM |
Flex Pharma (NASDAQ:FLKS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Flex Pharma (NASDAQ:FLKS) Income Statement, Balance Sheet and Cash Flow Statement
Flex Pharma (NASDAQ FLKS) Stock Chart for Friday, April, 20, 2018
Loading chart…
